Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma

References

• Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ. 2006. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet. 45(12):1227–1238.
   PubMed Web of Science ®Google Scholar
• Badagnani I, Castro RA, Taylor TR, Brett CM, Huang CC, Stryke D, Kawamoto M, Johns SJ, Ferrin TE, Carlson EJ, et al. 2006. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 318(2):521–529.
   PubMed Web of Science ®Google Scholar
• Beechinor RJ, Thompson PA, Hwang MF, Vargo RC, Bomgaars LR, Gerhart JG, Dreyer ZE, Gonzalez D. 2019. The population pharmacokinetics of high-dose methotrexate in infants with acute lymphoblastic leukemia highlight the need for bedside individualized dose adjustment: a report from the Children's Oncology Group. Clin Pharmacokinet. 58(7):899–910.
   PubMed Web of Science ®Google Scholar
• Cao M, Guo M, Wu DQ, Meng L. 2018. Pharmacogenomics of methotrexate: current status and future outlook. Curr Drug Metab. 19(14):1182–1187.
   PubMed Web of Science ®Google Scholar
• Caronia D, Patiño-Garcia A, Peréz-Martínez A, Pita G, Moreno LT, Zalacain-Díez M, Molina B, Colmenero I, Sierrasesúmaga L, Benítez J, et al. 2011. Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLOS One. 6(10):e26091.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD. 2002. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 62(11):3144–3150.
   PubMed Web of Science ®Google Scholar
• Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. 2003. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63(14):4048–4054.
   PubMed Web of Science ®Google Scholar
• Chitty KM, Chan B, Pulanco CL, Luu S, Egunsola O, Buckley NA. 2018. Discontinuities and disruptions in drug dosage guidelines for the paediatric population. Br J Clin Pharmacol. 84(5):1029–1037.
   PubMed Web of Science ®Google Scholar
• Colom H, Farré R, Soy D, Peraire C, Cendros JM, Pardo N, Torrent M, Domenech J, Mangues MA. 2009. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma. Ther Drug Monit. 31(1):76–85.
   PubMed Web of Science ®Google Scholar
• Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, Fanciullino R, Pourroy B, Deville JL, Duffaud F, Bagarry-Liegey D, et al. 2008. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs. 19(3):267–273.
   PubMed Web of Science ®Google Scholar
• Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH. 1986. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med. 314(8):471–477.
   PubMed Web of Science ®Google Scholar
• Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J. 2011. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol. 67(10):993–1006.
   PubMed Web of Science ®Google Scholar
• Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, Xuan k. H, Leblond V, Lechat P. 2006. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol. 58(5):626–633.
   PubMed Web of Science ®Google Scholar
• Gao X, Qian XW, Zhu XH, Yu Y, Miao H, Meng JH, Jiang JY, Wang HS, Zhai XW. 2021. Population pharmacokinetics of high-dose methotrexate in chinese pediatric patients with acute lymphoblastic leukemia. Front Pharmacol. 12:701452.
   PubMed Web of Science ®Google Scholar
• Gervasini G, Mota-Zamorano S. 2019. Clinical implications of methotrexate pharmacogenetics in childhood acute lymphoblastic leukaemia. Curr Drug Metab. 20(4):313–330.
   PubMed Web of Science ®Google Scholar
• Guichard N, Guillarme D, Bonnabry P, Fleury-Souverain S. 2017. Antineoplastic drugs and their analysis: a state of the art review. Analyst. 142(13):2273–2321.
   PubMed Web of Science ®Google Scholar
• Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 59(11):2532–2535.
   PubMed Web of Science ®Google Scholar
• Hou Z, Matherly LH. 2014. Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr. 73:175–204.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD. 2016. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Hu YH, Zhou L, Wang SS, Jing X, Guo HL, Sun F, Zhang Y, Chen F, Xu J, Ji X. 2019. Methotrexate disposition in pediatric patients with acute lymphoblastic leukemia: what have we learnt from the genetic variants of drug transporters. Curr Pharm Des. 25(6):627–634.
   PubMed Web of Science ®Google Scholar
• Huang X, Fang Q, Rao T, Zhou L, Zeng X, Tan Z, Chen L, Ouyang D. 2020. Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota. Toxicol Appl Pharmacol. 391:114900.
   PubMed Web of Science ®Google Scholar
• Hui KH, Chu HM, Fong PS, Cheng WTF, Lam TN. 2019. Population pharmacokinetic study and individual dose adjustments of high-dose methotrexate in chinese pediatric patients with acute lymphoblastic leukemia or osteosarcoma. J Clin Pharmacol. 59(4):566–577.
   PubMed Web of Science ®Google Scholar
• Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, Sastre A, Garcia de Andoin N, Garcia-Orad A. 2016. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genomics. 26(11):517–525.
   PubMed Web of Science ®Google Scholar
• Johansson ÅM, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF. 2011. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit. 33(6):711–718.
   PubMed Web of Science ®Google Scholar
• Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV. 2019. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 84(6):1339–1348.
   PubMed Web of Science ®Google Scholar
• Li XY, Li JQ, Luo XQ, Wu XD, Sun X, Xu HG, Li CG, Liu RY, Sun XF, Chen HQ, et al. 2021. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia – a multi-centric clinical study of GD-2008-ALL protocol. BMC Cancer. 21(1):59.
   PubMed Web of Science ®Google Scholar
• Lui G, Treluyer JM, Fresneau B, Piperno-Neumann S, Gaspar N, Corradini N, Gentet JC, Marec Berard P, Laurence V, Schneider P, et al. 2018. A pharmacokinetic and pharmacogenetic analysis of osteosarcoma patients treated with high-dose methotrexate: data from the OS2006/Sarcoma-09 trial. J Clin Pharmacol. 58(12):1541–1549.
   PubMed Web of Science ®Google Scholar
• Medellin-Garibay SE, Hernández-Villa N, Correa-González LC, Morales-Barragán MN, Valero-Rivera KP, Reséndiz-Galván JE, Ortiz-Zamudio JJ, Milán-Segovia RDC, Romano-Moreno S. 2020. Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 85(1):21–31.
   PubMed Web of Science ®Google Scholar
• Mei S, Li X, Jiang X, Yu K, Lin S, Zhao Z. 2018. Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma. J Pharm Sci. 107(5):1454–1460.
   PubMed Web of Science ®Google Scholar
• Min Y, Qiang F, Peng L, Zhu Z. 2009. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos. 30(8):437–447.
   PubMed Web of Science ®Google Scholar
• Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV, et al. 1996. Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer. 65(5):613–619.
   PubMed Web of Science ®Google Scholar
• Pai MP, Debacker KC, Derstine B, Sullivan J, Su GL, Wang SC. 2020. Comparison of body size, morphomics, and kidney function as covariates of high-dose methotrexate clearance in obese adults with primary central nervous system lymphoma. Pharmacotherapy. 40(4):308–319.
   PubMed Web of Science ®Google Scholar
• Panetta JC, Roberts JK, Huang J, Lin T, Daryani VM, Harstead KE, Patel YT, Onar-Thomas A, Campagne O, Ward DA, et al. 2020. Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours. Br J Clin Pharmacol. 86(2):362–371.
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, et al. 2013. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood. 121(6):898–904.
   PubMed Web of Science ®Google Scholar
• Ritchie C, Cordova AF, Hess GT, Bassik MC, Li L. 2019. SLC19A1 is an importer of the immunotransmitter cGAMP. Mol Cell. 75(2):372–381.e375.
   PubMed Web of Science ®Google Scholar
• Santucci R, Levêque D, Lescoute A, Kemmel V, Herbrecht R. 2010. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res. 30(9):3807–3810.
   PubMed Web of Science ®Google Scholar
• Schmiegelow K. 2009. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 146(5):489–503.
   PubMed Web of Science ®Google Scholar
• Schulte RR, Choi L, Utreja N, Van Driest SL, Stein CM, Ho RH. 2021. Effect of SLCO1B1 polymorphisms on high-dose methotrexate clearance in children and young adults with leukemia and lymphoblastic lymphoma. Clin Transl Sci. 14(1):343–353.
   PubMed Web of Science ®Google Scholar
• Shi ZY, Liu YO, Gu HY, Xu XQ, Yan C, Yang XY, Yan D. 2020. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. Biopharm Drug Dispos. 41(3):101–110.
   PubMed Web of Science ®Google Scholar
• Simon N, Marsot A, Villard E, Choquet S, Khe HX, Zahr N, Lechat P, Leblond V, Hulot JS. 2013. Impact of ABCC2 polymorphisms on high-dose methotrexate pharmacokinetics in patients with lymphoid malignancy. Pharmacogenomics J. 13(6):507–513.
   PubMed Web of Science ®Google Scholar
• Sun W, Wu RR, van Poelje PD, Erion MD. 2001. Isolation of a family of organic anion transporters from human liver and kidney. Biochem Biophys Res Commun. 283(2):417–422.
   PubMed Web of Science ®Google Scholar
• Suthandiram S, Gan GG, Zain SM, Bee PC, Lian LH, Chang KM, Ong TC, Mohamed Z. 2014. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 15(11):1479–1494.
   PubMed Web of Science ®Google Scholar
• Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB. 2020. MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase. Clin Pharmacol Ther. 108(3):635–643.
   PubMed Web of Science ®Google Scholar
• Taylor ZL, Vang J, Lopez-Lopez E, Oosterom N, Mikkelsen T, Ramsey LB. 2021. Systematic review of pharmacogenetic factors that influence high-dose methotrexate pharmacokinetics in pediatric malignancies. Cancers. 13(11):2837.
   PubMed Web of Science ®Google Scholar
• Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, et al. 2009. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol. 27(35):5972–5978.
   PubMed Web of Science ®Google Scholar
• Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. 2002. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62(17):5035–5040.
   PubMed Web of Science ®Google Scholar
• Wang SM, Sun LL, Wu WS, Yan D. 2018. MiR-595 suppresses the cellular uptake and cytotoxic effects of methotrexate by targeting SLC19A1 in CEM/C1 cells. Basic Clin Pharmacol Toxicol. 123(1):8–13.
   PubMed Web of Science ®Google Scholar
• Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL. 2014. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol. 31(7):62.
   PubMed Web of Science ®Google Scholar
• Xu HW, Xu L, Hao JH, Qin CY, Liu H. 2010. Expression of P-glycoprotein and multidrug resistance-associated protein is associated with multidrug resistance in gastric cancer. J Int Med Res. 38(1):34–42.
   PubMed Web of Science ®Google Scholar
• Yang L, Wu H, de Winter BCM, Sheng CC, Qiu HQ, Cheng Y, Chen J, Zhao QL, Huang J, Jiao Z, et al. 2020. Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. Cancer Chemother Pharmacol. 85(5):881–897.
   PubMed Web of Science ®Google Scholar
• Yuan X, Yu U, Chen S, Xu H, Yi M, Jiang X, Song J, Chen X, Chen S, Lin Z, et al. 2021. Case report: myeloid sarcoma development during treatment for B cell lymphoblastic lymphoma in a boy with KRAS/NRAS gene mutations. Onco Targets Ther. 14:347–353.
   PubMed Web of Science ®Google Scholar
• Zang YN, Wang SZ, Qin Y, Zhang JR, Zhao LB, Wang XL. 2019. Population pharmacokinetic study of delayed methotrexate excretion in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 57(8):402–407.
   PubMed Web of Science ®Google Scholar
• Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. 2001. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 61(19):7225–7232.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhai S, Yang L, Wu H, Zhang J, Ke X. 2010. Population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 48(1):11–21.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang Q, Tian X, Zhao H, Lu W, Zhen J, Niu X. 2015. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution. Chinese Med J. 128(1):111–118.
   PubMed Web of Science ®Google Scholar
• Zhou W, Parasrampuria DA, Nemat S, Nakahara S, Poggesi I, Massarella J, Zhang L, Appiani C. 2019. Population pharmacokinetic analysis of decitabine in pediatric patients with acute myeloid leukemia. J Clin Pharmacol. 59(5):668–676.
   PubMed Web of Science ®Google Scholar